Prescient Therapeutics Ltd has released a press release.
September 2022 Quarterly Update and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Prescient Therapeutics
- PTX-100 Trial Update
- Placement Results
- SPP Results and Placement
- PTX unveils CellPryme-A to boost CAR-T performance
- PTX strategic collaboration with MD Anderson Cancer Center
Later from Prescient Therapeutics
- AGM Presentation
- December 2022 Quarterly Update and Appendix 4C
- FDA grants broader orphan drug status to PTX100 for TCLs
- Continued promising results in PTX-100 TCL trial
- March 2023 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics